Polymorphisms in TNFA and TNFR2 affect outcome of unrelated bone marrow transplantation.
Effects of polymorphisms in TNFA and TNFR2 on the outcome of 462 cases of unrelated bone marrow transplantation (uBMT) were studied retrospectively. Four alleles of TNFA (U01-U04) distinguished by polymorphism in the upstream region, -1031 (T/C), -863 (C/A) and -857 (C/T), and two alleles of TNFR2 (196M/196R) distinguished by polymorphism at codon 196 were determined. Transplantation involving TNFA-U02- and/or U03-positive donors and/or recipients resulted in a higher incidence of graft-versus-host disease (GVHD) of grade III-IV (P < 0.05 for donor type, P < 0.01 for recipient type) and a lower relapse rate than that involving TNFA-U01 homozygous recipients and/or donors (P < 0.025 for donor type, P < 0.01 for recipient type). These results include the HLA mismatching effect due to linkage disequilibirium of TNFA with HLA loci. However, the effects were also observed in HLA-A, -B and -DRB1 allele-matched transplantation. Transplantation from TNFR2-196R-positive donors exhibited a higher incidence of severe GVHD (P < 0.05) and tendency for a lower relapse rate than that from TNFR2-196M homozygous donors. TNFR2-196R of recipient origin had no effect on GVHD but increased the relapse rate (P < 0.025). These results suggest that TNFA and TNFR2 typings are helpful for predicting uBMT outcome and for preventing severe complications at an early stage.
Ishikawa
Y
Y
Japanese Red Cross Central Blood Center, Tokyo, Japan.
Kashiwase
K
K
Akaza
T
T
Morishima
Y
Y
Inoko
H
H
Sasazuki
T
T
Kodera
Y
Y
Juji
T
T
D000328:Adult; D000741:Anemia, Aplastic / Q000628:therapy; D015703:Antigens, CD / Q000235:genetics*; D016026:Bone Marrow Transplantation; D003062:Codon / Q000235:genetics; D005260:Female; D030342:Genetic Diseases, Inborn / Q000628:therapy; D005838:Genotype; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000209:etiology / Q000235:genetics*; D006680:HLA Antigens / Q000235:genetics / Q000276:immunology; D019337:Hematologic Neoplasms / Q000628:therapy; D006648:Histocompatibility; D006801:Humans; D015994:Incidence; D015810:Linkage Disequilibrium; D008297:Male; D011110:Polymorphism, Genetic; D016016:Proportional Hazards Models; D018124:Receptors, Tumor Necrosis Factor / Q000235:genetics*; D047889:Receptors, Tumor Necrosis Factor, Type II; D012008:Recurrence; D012189:Retrospective Studies; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics*
D015703:Antigens, CD; D003062:Codon; D006680:HLA Antigens; D018124:Receptors, Tumor Necrosis Factor; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha